A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters The appetite for blockbuster weight loss and diabetes drugs is far from satisfied. From fresh competition to new uses, the market is quickly vaulting …
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. …
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug …
A little-known biotech company stunned the biopharmaceutical industry last spring when it declared an “unprecedented” achievement: its experimental cancer drug looked more effective than Merck‘s Keytruda in a clinical trial. The company, Summit Therapeutics, licensed the drug from Chinese company Akeso Inc. In October, a group of life science investors …
Anyone who’s been on a diet can likely relate: Those first lost pounds are met with a sense of euphoria. The voice inside one’s head screams: “I’ve got this!” But then, it inevitably becomes a slog. The initial novelty wears off, and the real work begins. Investors may see a …
Aykut Karahan | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Happy Friday! Buried in the election news this week was new data from drugmakers vying …
Election Day is here, and investors are on edge. The race between Vice President Kamala Harris and former President Donald Trump, as well as the battle for Congress, are down to the wire. The outcome will be consequential for markets on many fronts, including dictating policies that could hurt, or …
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The list …
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Eli Lilly, Novo Nordisk and other …
The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Scott Olson | Getty Images Novo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but their duopoly is closer than ever to facing a threat …